318 related articles for article (PubMed ID: 33199208)
1. Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis.
Kerneis M; Ferrante A; Guedeney P; Vicaut E; Montalescot G
Arch Cardiovasc Dis; 2020 Dec; 113(12):797-810. PubMed ID: 33199208
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
[TBL] [Abstract][Full Text] [Related]
3. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.
Matsuzawa Y; Kimura K; Ogawa H; Tamura K
Hypertens Res; 2022 Jul; 45(7):1147-1153. PubMed ID: 35581498
[TBL] [Abstract][Full Text] [Related]
4. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
5. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
6. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
Vitiello A; Ferrara F
Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection.
Sinha A; Vaggu RG; Swain R; Patnaik S
Curr Microbiol; 2023 Apr; 80(6):194. PubMed ID: 37106165
[TBL] [Abstract][Full Text] [Related]
8. Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.
Hasan SS; Kow CS; Hadi MA; Zaidi STR; Merchant HA
Am J Cardiovasc Drugs; 2020 Dec; 20(6):571-590. PubMed ID: 32918209
[TBL] [Abstract][Full Text] [Related]
9. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Ingraham NE; Barakat AG; Reilkoff R; Bezdicek T; Schacker T; Chipman JG; Tignanelli CJ; Puskarich MA
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341103
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
Koshy AN; Murphy AC; Farouque O; Ramchand J; Burrell LM; Yudi MB
Intern Med J; 2020 Dec; 50(12):1468-1474. PubMed ID: 33191600
[TBL] [Abstract][Full Text] [Related]
11. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
Edmonston DL; South AM; Sparks MA; Cohen JB
Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
[TBL] [Abstract][Full Text] [Related]
13. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19).
Albashir AAD
South Med J; 2021 Jan; 114(1):51-56. PubMed ID: 33398362
[TBL] [Abstract][Full Text] [Related]
14. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
[TBL] [Abstract][Full Text] [Related]
15. Hypertension and COVID-19: Current Evidence and Perspectives.
Gallo G; Calvez V; Savoia C
High Blood Press Cardiovasc Prev; 2022 Mar; 29(2):115-123. PubMed ID: 35184271
[TBL] [Abstract][Full Text] [Related]
16. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
[No Abstract] [Full Text] [Related]
17. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
[TBL] [Abstract][Full Text] [Related]
18. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
Lee MMY; Docherty KF; Sattar N; Mehta N; Kalra A; Nowacki AS; Solomon SD; Vaduganathan M; Petrie MC; Jhund PS; McMurray JJV
Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):165-178. PubMed ID: 33337478
[TBL] [Abstract][Full Text] [Related]
20. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
